GlaxoSmithKline's AIDS drugs business is to add one of its latest HIV medicines to a patent pool - cutting its future price for developing countries and pooling intellectual property rights. ViiV Healthcare, which is majority owned by the British drugmaker, said the agreement covered dolutegravir, a new antiretroviral medicine, for use in both adults and children with the human immunodeficiency virus (HIV) that causes AIDS. The move is a further victory for the new Medicines Patent Pool (MPP), which is trying to convince major drugmakers around the world to share rights to important medicines for developing countries with makers of cheap generic drugs.
Help employers find you! Check out all the jobs and post your resume.
